Valeo Pharma (TSE:VPH) has released an update.
Valeo Pharma Inc. has appointed Mr. Al Moghaddam as Chief Development Officer, a position focused on enhancing the company’s capital structure to support future growth, including potential mergers and acquisitions. Mr. Moghaddam, with over 25 years of experience in the life sciences industry, will be stepping down from the Board of Directors to take on this new role, aiming to bolster Valeo’s ambitious growth plans and expand its innovative drug portfolio.
For further insights into TSE:VPH stock, check out TipRanks’ Stock Analysis page.
